for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial

Aug 31 (Reuters) - GlaxoSmithKline PLC:

* GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL

* GSK - ADVANCE TO PHASE 3 FOLLOWS POSITIVE INTERIM PHASE 1/2 IMMUNOGENICITY AND SAFETY DATA

* GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL

* GSK - GLOBAL CLINICAL TRIAL WILL EVALUATE VACCINE CANDIDATE GBP510 AGAINST AZ/OXFORD COVID-19 VACCINE

* GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022, SUBJECT TO DATA AND REGULATORY REVIEW

* GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022

* GSK - NO SAFETY CONCERNS HAVE BEEN IDENTIFIED TO DATE IN THIS ONGOING STUDY.

* GSK - ALSO ASSESSING WHETHER AN INVESTIGATIONAL MONOCLONAL ANTIBODY, OTILIMAB, CAN HELP SEVERELY ILL COVID-19 PATIENTS AGED OVER 70

* GSK - GSK IS ALSO EXPLORING POTENTIAL THERAPEUTIC OR TREATMENT OPTIONS FOR COVID-19 PATIENTS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up